

# Pramodini B Kale-Pradhan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6572910/publications.pdf>

Version: 2024-02-01

49  
papers

1,017  
citations

516215

16  
h-index

433756

31  
g-index

49  
all docs

49  
docs citations

49  
times ranked

1621  
citing authors

#	ARTICLE	IF	CITATIONS
1	Tezepelumab in the Treatment of Uncontrolled Severe Asthma. <i>Annals of Pharmacotherapy</i> , 2023, 57, 62-70.	0.9	2
2	Mechanisms and Potential Roles of Glucose-Lowering Agents in COVID-19: A Review. <i>Annals of Pharmacotherapy</i> , 2021, 55, 1386-1396.	0.9	3
3	1297. Azithromycin vs Beta Lactams in Acute Exacerbations of COPD. <i>Open Forum Infectious Diseases</i> , 2021, 8, S737-S737.	0.4	0
4	Are Blacks at Higher Risk for Vancomycin-Related Acute Kidney Injury?. <i>Journal of Pharmacy Practice</i> , 2020, 33, 592-597.	0.5	3
5	Impact of Pharmacist Involvement in Heart Failure Transition of Care. <i>Annals of Pharmacotherapy</i> , 2020, 54, 239-246.	0.9	18
6	Combination of Vancomycin or Daptomycin and Beta-lactam Antibiotics: A Meta-analysis. <i>Pharmacotherapy</i> , 2020, 40, 648-658.	1.2	19
7	Dual Versus Mono-Bronchodilator Therapy in Moderate to Severe COPD: A Meta-analysis. <i>Annals of Pharmacotherapy</i> , 2020, 54, 1232-1242.	0.9	1
8	Adverse drug reactions in drug information databases: does presentation affect interpretation?. <i>Journal of the Medical Library Association: JMLA</i> , 2020, 108, 76-83.	0.6	2
9	Chapter 20: Prebiotics and Probiotics. , 2020, , .		0
10	556. Evaluation of Hydroxychloroquine-based Combination Therapies for the Treatment of COVID-19. <i>Open Forum Infectious Diseases</i> , 2020, 7, S343-S343.	0.4	0
11	49. Clinical Utility of Oseltamivir Restriction Policy. <i>Open Forum Infectious Diseases</i> , 2020, 7, S47-S47.	0.4	0
12	1469. Effect of Treatment Duration on Outcomes in Septic Patients Admitted for Urinary Tract Infections from Extended Care Facilities. <i>Open Forum Infectious Diseases</i> , 2019, 6, S536-S537.	0.4	0
13	2008. Outcomes of Patients with Positive Procalcitonin Levels Who Do Not Receive Continued Antibiotics. <i>Open Forum Infectious Diseases</i> , 2019, 6, S674-S674.	0.4	0
14	Biologic-Induced Infections in Inflammatory Bowel Disease: The TNF- $\alpha$ Antagonists. <i>Annals of Pharmacotherapy</i> , 2018, 52, 571-579.	0.9	12
15	Adherence to GOLD Guidelines in the Inpatient COPD Population. <i>Journal of Pharmacy Practice</i> , 2018, 31, 29-33.	0.5	12
16	Biosimilars in Inflammatory Bowel Disease - Accumulating Clinical Evidence. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 391-400.	1.3	4
17	Chapter 20: Prebiotics and Probiotics. , 2017, , .		1
18	Vancomycin-Related Renal Insufficiency: Does Race Play a Role?. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	0

#	ARTICLE	IF	CITATIONS
19	Is the Combination of Piperacillin-Tazobactam and Vancomycin Associated with Development of Acute Kidney Injury? A Meta-analysis. <i>Pharmacotherapy</i> , 2016, 36, 1217-1228.	1.2	71
20	New direct-acting antivirals in hepatitis C therapy: a review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvir. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 287-302.	1.3	31
21	Meta-Analysis. <i>Journal of Pharmacy Technology</i> , 2016, 32, 65-70.	0.5	6
22	Fluoroquinolone Sequential Therapy for <i>Helicobacter pylori</i> : A Meta-analysis. <i>Pharmacotherapy</i> , 2015, 35, 719-730.	1.2	12
23	Vulnerable COPD patients with comorbidities: the role of roflumilast. <i>Therapeutics and Clinical Risk Management</i> , 2014, 10, 969.	0.9	3
24	Teduglutide for the Treatment of Short Bowel Syndrome. <i>Annals of Pharmacotherapy</i> , 2014, 48, 1209-1213.	0.9	22
25	Effects of proton pump inhibitors on vitamin B12. <i>Maturitas</i> , 2014, 79, 1-2.	1.0	12
26	Effect of Bariatric Surgery on Hypertension. <i>Annals of Pharmacotherapy</i> , 2014, 48, 674-682.	0.9	95
27	Perils and pitfalls of long-term effects of proton pump inhibitors. <i>Expert Review of Clinical Pharmacology</i> , 2013, 6, 443-451.	1.3	101
28	The role of antimicrobials in Crohn's disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2013, 7, 281-288.	1.4	14
29	Roflumilast in the management of chronic obstructive pulmonary disease. <i>American Journal of Health-System Pharmacy</i> , 2013, 70, 2087-2095.	0.5	12
30	Early response of ceftaroline fosamil in the treatment of soft-tissue infections. <i>Expert Review of Clinical Pharmacology</i> , 2012, 5, 509-512.	1.3	2
31	Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis. <i>Expert Review of Clinical Pharmacology</i> , 2012, 5, 337-344.	1.3	116
32	Clinical Relevance of In Vitro Resistance of Echinocandins: a Focus on <i>Candida parapsilosis</i> . <i>Current Fungal Infection Reports</i> , 2012, 6, 107-112.	0.9	1
33	Treating Bugs with Bugs: The Role of Probiotics as Adjunctive Therapy for <i>Helicobacter pylori</i> . <i>Annals of Pharmacotherapy</i> , 2011, 45, 960-966.	0.9	50
34	Pancreatic Enzyme Products: Digesting the Changes. <i>Annals of Pharmacotherapy</i> , 2011, 45, 658-666.	0.9	18
35	Estimating Creatinine Clearance: A Meta-analysis. <i>Pharmacotherapy</i> , 2011, 31, 658-664.	1.2	47
36	Comparative Efficacy of Echinocandins and Nonechinocandins for the Treatment of <i>Candida parapsilosis</i> Infections: A Meta-analysis. <i>Pharmacotherapy</i> , 2010, 30, 1207-1213.	1.2	32

#	ARTICLE	IF	CITATIONS
37	Role of <i>Lactobacillus</i> in the Prevention of Antibiotic-Associated Diarrhea: A Meta-Analysis. <i>Pharmacotherapy</i> , 2010, 30, 119-126.	1.2	76
38	Combination of arginine and omega-3 fatty acids enteral nutrition in critically ill and surgical patients: a meta-analysis. <i>Expert Review of Clinical Pharmacology</i> , 2010, 3, 459-469.	1.3	8
39	Effectiveness of Probiotics in the Treatment of Irritable Bowel Syndrome. <i>Pharmacotherapy</i> , 2008, 28, 496-505.	1.2	24
40	Treatment and recurrence management of staphylococcal infections: community-acquired MRSA. <i>Expert Review of Anti-Infective Therapy</i> , 2008, 6, 909-915.	2.0	5
41	A review of infliximab use in ulcerative colitis. <i>Clinical Therapeutics</i> , 2008, 30, 223-230.	1.1	47
42	Multi-Matrix System Mesalamine: To Use or Not To Use. <i>Annals of Pharmacotherapy</i> , 2008, 42, 265-269.	0.9	11
43	Prevention of Postoperative Nausea and Vomiting. <i>Annals of Pharmacotherapy</i> , 2007, 41, 68-78.	0.9	48
44	Tegaserod for Constipation-Predominant Irritable Bowel Syndrome. <i>Pharmacotherapy</i> , 2007, 27, 267-277.	1.2	10
45	Novel Therapies for Crohn's Disease: Focus on Immunomodulators and Antibiotics. <i>Annals of Pharmacotherapy</i> , 2006, 40, 1804-1813.	0.9	10
46	Esomeprazole for Acid Peptic Disorders. <i>Annals of Pharmacotherapy</i> , 2002, 36, 655-663.	0.9	38
47	The Efficacy of Extended-Interval Dosing of Omeprazole in Keeping Gastroesophageal Reflux Disease Patients Symptom Free. <i>Annals of Pharmacotherapy</i> , 1999, 33, 638-641.	0.9	13
48	Enteral Nutrition in Patients with Pancreatitis. <i>Pharmacotherapy</i> , 1999, 19, 1036-1041.	1.2	4
49	Effect of body weight on aminoglycoside pharmacokinetics in patients with hypoalbuminemia. <i>American Journal of Health-System Pharmacy</i> , 1997, 54, 2201-2203.	0.5	1